Form 8-K HALOZYME THERAPEUTICS For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital
August 8, 2018 6:59 AM EDTBMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) while maintaining a Market Perform rating.
Analsyt Do Kim commented, "We raise our target to $21 from $19, as our probability of success for PEGPH20 in pancreatic cancer increases to 70% from 65%, following positive... More
